The product is obtained by removing the citrated plasma from the whole blood that has been allowed to stand or has been centrifuged to deposit the cells. The supernatant liquid is removed under aseptic conditions. The cells are matched with the recipient’s plasma and may then be mixed with matched cells from other bottles. The hemoglobin content must not be less than 15.5. The product must be used within 12 hours since there is a risk of bacterial contamination.

Uses: The product is used when the administration of whole blood is not necessary as in treatment of diseases such as chronic anemia. Large amounts of citrate are given with whole blood transfusions, which might lead to citrate toxicity in infants. Hence, red blood corpuscles are used in such cases.